Announcements Trials
Browse Landscape

Phase

Phase 2 145Phase 1/2 24Phase NA 16Phase 1 11Phase 3 10Phase 2/3 5Phase EARLY_PHASE1 1

Status

Unknown 5Recruiting 3Not yet recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Lymphoid 1Head & Neck 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Liver Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × camrelizumab × Clear all
NCT05062837 2024-01-23

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Guangxi Medical University

Phase 2/3 Unknown
62 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Unknown
460 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown
15 enrolled
Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

NCT04907344 2021-05-28

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Tianjin Medical University Cancer Institute and Hospital

Phase 2/3 Unknown
420 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04510610 2020-08-12

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Chinese PLA General Hospital

Phase 2/3 Unknown
100 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡